The occurrence of serious side-effects in human infants has led to the withdrawal of the live rotavirus vaccine. Rotavirus diarrhoea is a significant problem and vaccines are urgently needed. Rotavirus-like particles (VLFs) have shown promise as vaccines but not fulfilled their potential. Our objectives will establish if VLPs are an effective and commercially viable alternative. We will construct novel VLPs; monitor the induced immune responses and the mechanisms by which they are induced; design an optimal, practical immunization schedule; assess the efficacy of VLPs to prevent rotavirus diarrhoea; determine the parameters for optimal mass production of VLPs at low cost. Thus, we will have explored the vaccine potential of rotavirus VLPs from the molecular, immunological and commercial viewpoints.
Funding SchemeCSC - Cost-sharing contracts
171 82 Solna - 17182